News and Press Releases
Press releases
Canadian Clinical Study Sites Re-Commence Bladder Cancer Study
Toronto, Ontario – August 12, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment Toronto,...
0Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19
Toronto, Ontario – June 30, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase Receives FDA IND Authorization
Toronto, Ontario – May 19, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical sta...
0Theralase Releases 2019 Financial Results
Toronto, Ontario – April 29, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceut...
0Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study
Toronto, Ontario – March 20, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage ...
0Theralase Advances its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia
Toronto, Ontario – February 25, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase Technologies Awarded 2020 TSX Venture 50
Toronto, Ontario – February 20, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase Granted US Patent for Multiwavelength Photodynamic Therapy
Toronto, Ontario – January 27, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online
TORONTO, ON / January 16, 2020 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceu...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.